|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.29/-1.19
|
企業價值
250.27M
|
資產負債 |
每股賬面淨值
4.77
|
現金流量 |
現金流量率
--
|
損益表 |
收益
2.81M
|
每股收益
0.05
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/01/11 18:06 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. |